Compare Natera Inc. Common Stock (NTRA) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs UnitedHealth Group Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while UnitedHealth Group Inc trades at $396.94 (market cap $339.08B). The key difference: UnitedHealth Group Inc is far larger — about 5.9× Natera Inc. Common Stock's market cap, and UnitedHealth Group Inc pays a 2.46% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| NTRA | UNH | |
|---|---|---|
Market Cap | $57.03B | $339.08B |
Volume | 1,131,157 | 12,648,635 |
Sector | Health | Health |
52-Week High | $425.64 | $436.35 |
52-Week Low | $179.42 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $56.18B | $380.94B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
UnitedHealth Group (UNH) trades at $378.52, down 0.21% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats in recent quarters, including Q3 2026 EPS of $4.69 beating expectations of $4.14. Revenue growth remains solid at $447.57B for 2025, though net margins have compressed to 3.14%. Recent developments include strategic moves with TPG for WellMed operations and continued AI investments in Optum Insight.
UNH presents a compelling investment case with 82.7% analyst buy ratings and a $470.11 consensus price target representing 24% upside. The company's Medicare Advantage strength and Optum improvements support growth, though regulatory scrutiny and medical cost pressures remain key risks. Strong institutional ownership and Michael Burry's recent call option position signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
